Latest Albireo AB Stories
GOTHENBURG, Sweden, February 5, 2015 /PRNewswire/ -- Albireo today announced initiation of a phase II trial with A4250, the company's lead compound for cholestatic liver
GOTHENBURG, Sweden, October 12, 2010 /PRNewswire/ -- Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial.
GOTHENBURG, Sweden, April 29, 2010 /PRNewswire/ -- Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.